-7 -and other disease (OD) samples including HIV+ and HIV-samples, 2) All TB and LTB 138 samples including HIV+ and HIV-samples (i.e. OD excluded), 3) All HIV+ TB and LTB 139 samples, (i.e. all HIV-and OD excluded), 4) All HIV-TB and LTB samples (i.e. all HIV+ 140 and OD excluded). Models were trained to simultaneously predict both the TB and HIV status 141 of each training sample, i.e. models trained on subset 1) explicitly classified samples as one of 142 6 classes: TB:HIV+, TB:HIV-, LTB:HIV+, LTB:HIV-, OD:HIV+, or OD:HIV-; models 143 trained on subset 2) classified samples as one of 4 classes TB:HIV+, TB:HIV-, LTB:HIV+, 144 or LTB:HIV-, and models trained on subsets 3) and 4) were binary models that classified 145 samples as TB or LTB only, as HIV status was constant in these subsets. 146
After models were trained on the initial 554 probes, the models were sequentially shrunk to 147 obtain probe-reduced models that only comprised the most important 250, 50, 25, 15, or 10 148 probes from the initial set. Probe importance rankings were calculated using the varImp 149 function supplied by the caret package. This function implements algorithm-specific methods 150 for evaluating how much each probe contributes to the classification performance of the 151 model. In the case of random forests, the difference in out-of-bag error [19] with and without 152 the inclusion of a single probe was used to rank the probes in order of importance. For 153
Elastic-net logistic regression models, the probe variable coefficient was used to rank the 154 probes. For Neural Networks, Garson's algorithm [20] was used to calculate probe importance 155 from network weights. For Random Forests, probe importance was measured as the 156 difference in predictive performance comparing all trees that contain the probe with trees that 157 lack that probe. For the remaining modelling approaches (SVM, KNN), the univariate 158 predictive power of the individual probe was used to rank importance in an algorithm-159 independent way. 160
For each algorithm-subset combination, the most important 250 out of the original 554 probes 161
were selected, the model re-trained on this subset of probes, and this probe-reduced model 162 used to predict the left-out sample. This procedure was then repeated to iteratively shrink each 163 model to contain the 50, 25, 15 and 10 most important probes from the previous step. This 164 entire process was carried out for each held-out sample in the cross validation so that the 165 -8 -sequential shrinking and prediction steps were performed independently for every held out 166 sample. 167
168
Training performance was assessed using leave-one-out cross validation (LOOCV). Initially, 169 a single sample from the overall training set was held out, then a classifier model was trained 170 on the remaining samples, and used to predict the status of the held-out sample. This 171 procedure was repeated for every training sample, and model performance was then 172 calculated using predictions on the held-out samples. Areas under the ROC curves (AUCs) 173 for model discrimination of TB vs non-TB samples in the training subset were calculated for 174 predictions on the held out samples, and this was used as the performance metric for initial 175 model structure selection. For models that predicted more than 2 classes, TB predictions were 176 calculated as the sum of TB-related prediction classes, e.g for 6 class models the overall TB 177 prediction value was calculated as the TB:HIV+ prediction value plus the TB:HIV-prediction 178 value. 179
Only "small" models (i.e., those consisting of 10, 15 or 25 probes) were considered for 180 application to the test sets. To choose the algorithm/class-complexity/training set between 181 these 3 probe sizes, initially the 10-probe model was selected. If either the 15 After models were selected by recursive LOOCV evaluation as described above, each 188 selected model was retrained using the most-commonly selected features from the LOOCV 189 and re-parameterised on the entire relevant training data subset. Predictions were made using 190 the predict function from the caret package to calculate class probabilities, and prediction 191 accuracies were assessed by calculating TB vs non-TB ROC curves using the R pROC 192 -9 -package. As described for the LOOCV procedure above, in the case ofmodels that predicted 193 more than 2 classes, TB predictions were calculated as the sum of TB-related prediction 194
classes, e.g for 6 class models the overall TB prediction value was calculated as the TB we term the 'ACS' signature (referring to the Adolescent Cohort Study from which the 200 signature was derived). For predictions using the threeGene signature, datasets were 201 downloaded in raw non-normalised format from GEO before being quantile normalised and 202 baseline corrected using the log-exponential method using the R limma package [22] . The 203 threeGene score was then directly calculated as (GBP5 + DUSP3)/2 -KLF2. For the ACS 204 model predictions, datasets were prepared and normalised and scored as described in [23] . The p-value of the model coefficients a, b and c were calculated using the R summary.lm 213 function, and a false discovery rate correction applied. 214
215
Gene set enrichment analysis 216
Gene set enrichment analysis was performed using the R tmod[24] package, using the blood 217 transcriptional gene sets previously described by Li et al [25] and Chaussabel et al [26] . P-218 -10 -values were calculated using the hypergeometric test as implemented in the tmodHGtest 219 function, using all included microarray gene symbols as the background. 220
Results

221
Development, cross-validation and selection of multinomial machine learning 222 models for predicting TB and HIV. 223
We used data from a previously-published cohort (OD). Roughly half of these individuals were also HIV+ ( Table 1 ). These transcriptional 227 profiles were used to develop and test multinomial machine learning approaches to 228 specifically identify each symptomatic subset. 229
Machine learning models were trained on the South African adult dataset described in Table  230 1, with the Malawian adults used as an independent test set. In order to focus on the strongest 231 signal probes, an initial down-selection step was performed where only probes with a log2 232 normalised expression interquartile range of at least 1.5 in the South African set were 233 considered for model training (554 probes). 234
Models were trained to classify all or relevant subsets of the data into 2 (binary classifier), 4 235 (multinomial), or 6 (multinomial) classes, using a diverse panel of machine-learning 236 algorithms. Two-class models were trained to classify a sample as either active or latent TB. 237
Two different two class models were trained for each algorithm, one on HIV-TB and LTB 238 samples only, and another on HIV+ TB and LTB samples only. Four-class models were 239 trained to classify a sample as active or latent TB and as HIV+ or HIV-simultaneously, using 240 all TB and LTB samples, both HIV+ and HIV-. Six-class models were trained to classify a 241 sample as active TB, latent TB or other disease, and as HIV+ or HIV-, and were trained on 242 the entire dataset, including TB, LTB and OD, both HIV+ and HIV-. The Malawian adults were used as an independent test set for the selected models. 266 To more thoroughly validate the six-class multinomial model, classification performance was 275 evaluated using three additional previously-published whole-blood microarray datasets[10-276 12]. To reduce technical sources of variability as much as possible, test sets were selected that 277 used the same Illumina HumanHT-12 microarray platform as was used for the Kaforou 278 cohort. These additional test sets comprised a broad range of samples, including adult and 279 childhood TB; TB vs other inflammatory, bacterial and pulmonary diseases; and samples 280 taken from a range of geographical locations (Table 3 ). The two-class HIV-model was also 281 included as a comparator for the six-class multinomial model. Analysis of the genes comprising the 10-gene six-class signature identified LAG3 and 327 CERKL as exhibiting distinct expression patterns. As the signature genes reflect a minimal 328 set of genes necessary to classify disease states, we hypothesised that there may be other 329 genes closely correlated with LAG3 and CERKL that could shed light on the biological 330 processes driving the opposing regulation they exhibit. 331
The expression of LAG3 was correlated very tightly (Spearman ρ > 0.8, p< 1e-32), with a set 332 of eight genes similarly downregulated in active TB and upregulated in HIV (Table S2 , 333 
Conclusions
391
We have identified a broadly applicable active TB-specific 10-gene multinomial signature by 392 validating candidate signatures with successively harder problems: training a diverse panel of 393 candidate models on an adult test set; making blind predictions an independent adult test set 394 from a different geographical cohort, albeit from the same study; making blind predictions on 395 the combination of the adult test set with three additional independent cohorts; and finally 396 testing for discrimination of HIV+ TB from HIV-TB. 397
While the signature shown here does not reach the diagnostic sensitivity required to be a 398 practical alternative to sputum culture for clinical use (>98% sensitivity for culture positive 399 TB) [3] , it represents an incremental performance improvement over previously described 400 signatures. All of the blood-based signatures evaluated in this work (the ten-gene six-class 401 signature, the threeGene signature and the ACS signature) show similar performance on the 402 test datasets examined here, performance which falls below that observed with traditional 403 sputum culture. While whole blood gene expression signatures do not appear likely to 404 -17 -approach the performance of liquid culture, it is possible that whole blood signatures can be 405 developed to improve diagnosis of TB cases who cannot produce sputum or who have 406 paucibacillary disease, including HIV+ TB cases. Unfortunately, the lack of a "gold-standard" 407 method of diagnosing TB when sputum culture cannot be obtained makes it extremely 408 difficult to accurately evaluate blood transcriptional signatures in this context. 409
A possible practical application of this test is as a high-specificity "triage test" that can rule 410 out patients unlikely to have TB, and identify persons who should receive a full sputum 411 culture, thus reducing the necessity of working with difficult-to-acquire and potentially 412 infectious sputum samples. At an operating point of 95% sensitivity, the ten-gene random 413 forest shows a specificity of 47%. In a situation such as a medical clinic in a TB-endemic 414 area, assuming 50% of patients presenting with symptoms consistent with TB have active TB, 415 treating signature positive patients immediately would almost half the amount of sputum 416 culture necessary. 417 probes>. E.g. six.rf.10 is the 10 probe random forest model trained to predict 6 classes. 573 twoneg and twopos refer to 2-class models trained on HIV-or HIV+ samples respectively. 574 threeGene refers to the signature described by Khatri et al [32] , and ACS refers to the 575 signature described by Zak et al [23] . A ROC curves for classification of the Malawi test 576 samples from the Kaforou cohort. B ROC curves for Malawi test set plus the three further 577 independent test sets described in Table 3 
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